GLP-1 Medications for Weight Loss: A Science-Based Comparison of Every Major Option

The weight loss drug conversation used to be simple — and not in a good way. For decades, the options were limited, the results were modest, and the side effects were often worse than the problem. Then GLP-1 receptor agonists arrived, and the clinical data rewrote what we thought was possible. The landmark STEP 1 trial showed that once-weekly semaglutide at 2.4 mg produced an average body weight reduction of nearly 15% over 68 weeks — a number that, not long ago, would have been dismissed as too good to be credible. And that was just the beginning.

Today, the GLP-1 landscape has expanded dramatically. You’re no longer choosing between “medication” and “no medication” — you’re navigating a growing menu of injectable peptides, oral formulations, combination therapies, and next-generation compounds that are pushing weight loss outcomes closer to what bariatric surgery has historically achieved. For men who are serious about their metabolic health, understanding the real differences between these options — not just the marketing — is essential.

This comparison is built entirely on peer-reviewed clinical trial data. No anecdotes, no influencer takes. Just the science, applied practically to help you and your physician have a smarter conversation about which direction makes sense for your body and your goals.

The Established Players: Semaglutide and Liraglutide

If you’ve heard of one GLP-1 medication, it’s almost certainly semaglutide — sold as Ozempic for diabetes and Wegovy for obesity. It’s the compound that put this entire drug class on the cultural map, and the clinical evidence supporting it is substantial. The STEP 1 trial enrolled 1,961 adults with obesity who did not have diabetes, and after 68 weeks of weekly 2.4 mg injections combined with lifestyle counseling, participants lost an average of 14.9% of their body weight compared to 2.4% in the placebo group. More telling are the responder rates: 86.4% of semaglutide users achieved at least 5% weight loss, 69.1% hit 10%, and 50.5% crossed the 15% threshold — numbers that dwarf anything previous pharmacotherapy had demonstrated.

But semaglutide didn’t emerge in a vacuum. Liraglutide — sold as Saxenda for weight management — came first, and for a period it was the gold standard injectable GLP-1 for obesity. It requires daily injections rather than weekly, and its efficacy, while real, is meaningfully lower. The STEP 8 trial put both drugs head-to-head in the same randomized trial, which is exactly the kind of direct comparison that’s usually missing from these conversations. The results were not close. Semaglutide 2.4 mg produced an average weight loss of 15.8% versus just 6.4% with liraglutide 3.0 mg — a difference of 9.4 percentage points. When it came to achieving 20% or more weight loss, 38.5% of semaglutide users got there compared to just 6% of liraglutide users.

There’s another practical dimension that matters for real-world adherence: tolerability. Despite both drugs sharing a similar gastrointestinal side effect profile — nausea, diarrhea, and vomiting being the most common — 27.6% of liraglutide users discontinued treatment versus only 13.5% of semaglutide users. The daily injection burden likely contributes to that dropout rate. For most men evaluating their options, the evidence strongly favors semaglutide over liraglutide if injectable weekly GLP-1 therapy is the direction they’re heading. Liraglutide still has a role for patients who have specific clinical reasons to use it, but as a first-line choice for weight loss, it’s been largely superseded.

Both semaglutide and liraglutide work through the same fundamental mechanism: they mimic the naturally occurring GLP-1 hormone, which slows gastric emptying, reduces appetite through central nervous system signaling, and improves insulin sensitivity. The difference in outcomes between them reflects semaglutide’s longer half-life, its higher binding affinity for the GLP-1 receptor, and the tolerability advantages that come with once-weekly versus daily dosing. The lesson here is that within the same drug class, formulation details matter enormously.

Tirzepatide and the Dual-Agonist Advantage

If semaglutide raised the ceiling on what weight loss medication could achieve, tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — may have raised it again. Tirzepatide is not a pure GLP-1 agonist. It’s a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP is another incretin hormone involved in metabolic regulation, and combining both pathways appears to produce additive or even synergistic effects on weight reduction.

The SURPASS-2 trial compared tirzepatide directly against semaglutide — though importantly, this was in patients with type 2 diabetes, using a lower dose of semaglutide (1 mg, the diabetes dose) rather than the 2.4 mg weight management dose. Even so, the findings are illuminating. Tirzepatide at all three doses (5 mg, 10 mg, and 15 mg) was both noninferior and superior to semaglutide 1 mg in reducing HbA1c, and the weight reductions were consistently greater with tirzepatide — by 1.9 kg at the 5 mg dose, 3.6 kg at 10 mg, and 5.5 kg at 15 mg. The side effect profiles were broadly similar between the two drugs, with gastrointestinal events being the primary concern in both groups.

The obesity-specific tirzepatide trials (SURMOUNT program) have shown even more dramatic results, with some participants achieving 20% to 25% or more weight loss at the highest doses. For context, that level of weight reduction begins to approach the outcomes seen with surgical interventions like sleeve gastrectomy. The practical implication for men weighing their options is straightforward: if you have access to tirzepatide and your physician agrees it’s appropriate, the data currently positions it as the most effective approved injectable therapy for weight loss. That said, it’s also newer, more expensive in many markets, and insurance coverage remains inconsistent — all factors that shape real-world decision-making.

One important nuance worth understanding: the GIP mechanism in tirzepatide is still being studied in terms of exactly how it contributes to weight loss outcomes. Some researchers believe GIP receptor activation enhances tolerability of the GLP-1 component, allowing patients to reach higher effective doses with fewer side effects. Others point to direct metabolic effects on adipose tissue. The mechanistic debate continues, but the clinical outcome data is clear enough to act on.

What’s Coming: Oral GLP-1s and Next-Generation Combinations

The injectable nature of current GLP-1 therapies is one of the most common barriers men cite when discussing whether to start. Weekly injections are manageable for most people, but the needle aversion is real, and for men who travel frequently or have irregular schedules, the cold storage requirements and injection routine add friction. That friction may be largely eliminated within the next few years as oral GLP-1 formulations reach the market.

Orforglipron, developed by Eli Lilly, represents a genuinely novel approach. Rather than a peptide analog that must be injected to avoid digestive degradation, orforglipron is a small-molecule, nonpeptide GLP-1 receptor agonist — meaning it can be taken as a standard oral pill, once daily, with no special timing restrictions around food or water that currently limit oral semaglutide (Rybelsus). The phase 3 ATTAIN-1 trial, published in 2025, enrolled 3,127 adults with obesity without diabetes and tested three doses against placebo over 72 weeks. The highest dose of 36 mg produced an average weight loss of 11.2%, with 54.6% of participants losing at least 10% of body weight and 36% losing 15% or more. The 6 mg and 12 mg doses produced 7.5% and 8.4% average weight loss, respectively.

To put those numbers in context: orforglipron’s top-line efficacy at the highest dose is somewhat below what injectable semaglutide 2.4 mg achieves, but it’s substantially above what liraglutide 3.0 mg delivers — and it’s a pill. The cardiometabolic benefits were also meaningful, with significant improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol compared to placebo. Side effects followed the expected GLP-1 pattern of predominantly gastrointestinal events, mostly mild to moderate, with discontinuation rates between 5.3% and 10.3% depending on dose. For men who would otherwise not pursue injection-based therapy, an oral option achieving 11% weight loss represents a clinically meaningful alternative.

Even further along the efficacy curve is the combination of cagrilintide and semaglutide, known as CagriSema — a dual-hormone approach that pairs a GLP-1 agonist with an amylin analog. Amylin is a pancreatic hormone that complements GLP-1’s appetite-suppressing effects through separate pathways, and early data suggested the combination might push outcomes into genuinely transformative territory. The REDEFINE 1 phase 3 trial, published in 2025, confirmed that hypothesis. In 3,417 adults with overweight or obesity without diabetes, CagriSema produced an estimated mean weight reduction of 20.4% over 68 weeks, compared to 3.0% with placebo — a treatment difference of 17.3 percentage points. Participants reaching 25% or more and 30% or more weight loss were also assessed as confirmatory endpoints, and the results were statistically significant across all thresholds.

Twenty percent average weight loss in a drug trial is extraordinary. It’s a number that compresses the gap between pharmacotherapy and bariatric surgery to a degree that reframes the entire clinical conversation about obesity treatment. Gastrointestinal side effects affected 79.6% of CagriSema participants — higher than most single-agent GLP-1 trials — though events were predominantly transient and mild to moderate. CagriSema is not yet approved and its commercial path is still being determined, but for men with significant obesity-related health burden, it represents a potential option that didn’t exist even two years ago.

How to Think About These Options Practically

Reading through clinical trial data is one thing. Translating it into a decision framework that accounts for your actual life — your schedule, your insurance, your physician’s experience, your tolerance for side effects, and your specific health goals — is another. Here’s how to approach that translation without oversimplifying.

Start with what the data actually tells you about magnitude of effect. If your goal is modest weight loss to move a metabolic marker or reduce joint load, liraglutide or lower-dose orforglipron (if it becomes available) may be more than sufficient, and their lower potency isn’t inherently a weakness. If you’re dealing with significant obesity — BMI over 35, multiple cardiometabolic risk factors, or weight that’s materially limiting your quality of life — the strongest available options matter more, and the SURPASS-2 and REDEFINE 1 data suggest tirzepatide and emerging combination therapies deserve serious consideration.

Adherence is a clinical outcome in itself. The best medication in the world doesn’t help if you stop taking it, and discontinuation rates in these trials — even at controlled research sites with intensive support — ranged from 13% to 28%. The real-world dropout rates are likely higher. This means tolerability and dosing convenience should weigh heavily in your decision. The head-to-head STEP 8 data showing substantially lower discontinuation with weekly semaglutide versus daily liraglutide is a useful reminder that how you take a drug affects whether you take it.

Muscle preservation deserves explicit attention for men specifically. GLP-1 medications produce weight loss through caloric restriction — which means without deliberate resistance training and adequate protein intake, a portion of the weight lost will be lean mass rather than fat. This is not unique to GLP-1 drugs; it’s a fundamental challenge of any caloric deficit. But given the rapid and substantial weight loss these medications can produce, the risk of muscle loss is proportionally higher. Any man on a GLP-1 medication who isn’t actively resistance training and targeting 1.6 to 2.2 grams of protein per kilogram of body weight daily is leaving significant body composition outcomes on the table — and potentially trading metabolic health for scale wins that don’t hold up long-term.

Cost and access are not footnotes — they’re often the deciding factor. Semaglutide (Wegovy) and tirzepatide (Zepbound) carry list prices in the United States that can exceed $1,000 per month without insurance coverage, and coverage remains inconsistent and in flux depending on your plan, state, and diagnosis. Compounded versions of semaglutide and tirzepatide became widely available during shortage periods, though the FDA has taken steps to restrict compounding as shortages resolved. Orforglipron, if approved, could potentially change the economics given its manufacturing simplicity as a small molecule — oral pills are generally cheaper to produce than peptide injectables — though pricing will ultimately depend on competitive dynamics and payer negotiations.

Finally, these medications work best as part of a coherent lifestyle architecture, not as a replacement for one. Every major trial cited here included dietary counseling and physical activity recommendations alongside the medication. The participants who achieved 20% or more weight loss weren’t doing the medication alone — they were eating differently, moving more, and using the appetite suppression the drug provided as a window to build sustainable habits. For men who approach GLP-1 therapy as a tool within a broader health strategy rather than an end in itself, the outcomes data is genuinely encouraging. For those who view it as a bypass around behavioral change, the high relapse rates seen when these medications are discontinued tell a cautionary story.

The Takeaway

The GLP-1 medication landscape in 2025 looks nothing like it did five years ago, and it will likely look different again by 2027. What’s clear right now is this: injectable semaglutide 2.4 mg remains a clinically validated, widely used option with strong efficacy data. Tirzepatide has surpassed it in head-to-head comparisons and represents the current peak of approved therapy for most men. Oral orforglipron is closing the gap for those who cannot or will not inject, and CagriSema is pointing toward a future where 20% or more average weight loss from a medication becomes routine rather than extraordinary.

None of these drugs are magic, and none of them are trivial decisions. But for men navigating serious metabolic challenges — or simply trying to understand what the science actually says about the options available to them — the data has never been more useful, or more actionable. Bring the specific trial numbers to your physician. Ask which option fits your profile. And build the training and nutrition foundation that will make whatever you choose actually stick.